MS May Be Two Diseases, Not One, Study Finds

For decades, doctors have struggled to explain why multiple sclerosis hits every patient differently. Now, researchers may have found the answer: what we call MS might actually be two separate diseases hiding under one name.

Scientists at University College London studied 634 people with MS and uncovered something unexpected. Using brain scans and blood tests, they found two completely different patterns of how the disease attacks the brain.

In one group, damage started early in the brain's outer layer called the cortex. In the other, destruction focused on white matter deep inside the brain. Even more revealing, one type progressed slowly while the other moved fast.

This discovery helps solve a puzzle that has frustrated patients and doctors for years. Two people can have the same MS diagnosis, take the same medication, and experience completely different results. One person improves while the other doesn't respond at all.

The research team used a machine learning system called SuStaIn to spot patterns that human eyes might miss. By combining MRI brain scans with measurements of a protein released when nerve cells die, they could see exactly how damage spread through the brain over time.

The implications reach far beyond the lab. If MS really is two diseases, doctors could eventually predict which patients face faster decline and which treatments will actually work for them. Right now, finding the right therapy often feels like guesswork.

The researchers measured a protein called neurofilament light chain in the blood, which spikes when nerves get damaged. Paired with detailed brain imaging, this combo revealed the hidden split between the two disease types.

Why This Inspires

This research represents hope for the 2.8 million people worldwide living with MS. For too long, patients have faced uncertainty about their future and whether their treatment will help. Understanding that MS follows distinct biological paths means doctors can move toward truly personalized medicine.

Catching disease worsening earlier could help patients start the right treatments sooner. And for researchers hunting for better therapies, knowing they're actually dealing with two diseases opens entirely new directions for drug development.

The next step involves testing these findings in larger, more diverse patient groups to confirm the patterns hold true everywhere. The approach isn't ready for clinics yet, but the foundation is solid.

After years of treating symptoms without understanding the root causes, medicine is finally catching up to the complexity patients have experienced all along.